Chemomab Gains Board Strength as Melincoff Options Signal Governance Shift
How Chemomab’s new board shake‑up and insider sales could drive a strategic pivot and a potential price rebound.
2 minutes to read
CHEMOMAB THERAPEUTICS LTD
Chemomab Insider Confidence Signals Potential Upside Amid Fibrosis Pipeline
Chemomab’s insider confidence and rising social buzz point to potential upside for its fibrosis‑focused CB‑12 pipeline, but investors must weigh clinical milestones, regulatory milestones, and financial risk in a $12M‑cap biotech.
4 minutes to read
Insider Moves, Phase IIb Success: Chemomab Therapeutics Eyes First‑In‑Class TGF‑β Approval
Discover how Chemomab’s insider moves and breakthrough Phase‑IIb antifibrotic data could signal a first‑in‑class TGF‑β inhibitor’s regulatory future—and what it means for investors.
4 minutes to read